Hospital Pharmacy, LMU University Hospital, LMU Munich, Munich, Germany.
Doctoral Program Clinical Pharmacy, LMU University Hospital, LMU Munich, Munich, Germany.
BMC Geriatr. 2024 May 13;24(1):422. doi: 10.1186/s12877-024-05005-1.
Postoperative delirium (POD) is the most common complication following surgery in elderly patients. During pharmacist-led medication reconciliation (PhMR), a predictive risk score considering delirium risk-increasing drugs and other available risk factors could help to identify risk patients.
Orthopaedic and trauma surgery patients aged ≥ 18 years with PhMR were included in a retrospective observational single-centre study 03/2022-10/2022. The study cohort was randomly split into a development and a validation cohort (6:4 ratio). POD was assessed through the 4 A's test (4AT), delirium diagnosis, and chart review. Potential risk factors available at PhMR were tested via univariable analysis. Significant variables were added to a multivariable logistic regression model. Based on the regression coefficients, a risk score for POD including delirium risk-increasing drugs (DRD score) was established.
POD occurred in 42/328 (12.8%) and 30/218 (13.8%) patients in the development and validation cohorts, respectively. Of the seven evaluated risk factors, four were ultimately tested in a multivariable logistic regression model. The final DRD score included age (66-75 years, 2 points; > 75 years, 3 points), renal impairment (eGFR < 60 ml/min/1.73m, 1 point), anticholinergic burden (ACB-score ≥ 3, 1 point), and delirium risk-increasing drugs (n ≥ 2; 2 points). Patients with ≥ 4 points were classified as having a high risk for POD. The areas under the receiver operating characteristic curve of the risk score model were 0.89 and 0.81 for the development and the validation cohorts, respectively.
The DRD score is a predictive risk score assessable during PhMR and can identify patients at risk for POD. Specific preventive measures concerning drug therapy safety and non-pharmacological actions should be implemented for identified risk patients.
术后谵妄(POD)是老年患者手术后最常见的并发症。在药剂师主导的药物重整(PhMR)期间,考虑到谵妄风险增加的药物和其他可用风险因素的预测风险评分可以帮助识别风险患者。
2022 年 3 月至 10 月,对接受 PhMR 的年龄≥18 岁的骨科和创伤外科患者进行了回顾性观察性单中心研究。研究队列随机分为开发和验证队列(6:4 比例)。通过 4A 测试(4AT)、谵妄诊断和图表审查评估 POD。通过单变量分析测试 PhMR 时可用的潜在风险因素。有意义的变量被添加到多变量逻辑回归模型中。基于回归系数,建立了一个包含谵妄风险增加药物的 POD 风险评分(DRD 评分)。
在开发和验证队列中,分别有 42/328(12.8%)和 30/218(13.8%)的患者发生 POD。在评估的七个风险因素中,有四个最终在多变量逻辑回归模型中进行了测试。最终的 DRD 评分包括年龄(66-75 岁,2 分;>75 岁,3 分)、肾功能损害(eGFR<60ml/min/1.73m,1 分)、抗胆碱能药物负担(ACB 评分≥3,1 分)和谵妄风险增加药物(n≥2;2 分)。≥4 分的患者被归类为患有 POD 的高风险。风险评分模型的开发和验证队列的受试者工作特征曲线下面积分别为 0.89 和 0.81。
DRD 评分是一种可在 PhMR 期间评估的预测风险评分,可以识别发生 POD 的风险患者。对于确定的风险患者,应实施针对药物治疗安全性和非药物治疗的具体预防措施。